High Resolution Anuscopy Study

Last updated: February 14, 2025
Sponsor: Universitair Ziekenhuis Brussel
Overall Status: Active - Recruiting

Phase

N/A

Condition

Anal Dysplasia

Squamous Cell Carcinoma

Rectal Cancer

Treatment

HRA

Clinical Study ID

NCT06697964
HRA Study
  • Ages > 18
  • All Genders

Study Summary

The majority of anal squamous cell carcinomas (SCC) stem from infection with high-risk human papillomavirus (HPV). Anal SCC is rare among the general population but affects several populations disproportionately.

High-risk groups are screened through anal swabs for anal cytology and detection of high risk human papillomavirus (HR HPV). HRA referral is recommended for individuals with abnormal cytology.

HRA represents the only method to identify precancerous lesions of the anal canal, with only few specialists knowledgeable about it.

At UZ Brussel, the investigators collected a wealth of data about HPV infection and its association with anal pathology. By establishing a comprehensive study, the investigators can delve into this data with specific research questions, conducting valuable research to provide answers to pressing clinical questions and contribute to advancements in medical understanding and treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All patients who have undergone HRA and all future patients referred for HRA in UZBrussel

  • 18 years or older

  • Understands and able to speak and write in French, Dutch or English

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: HRA
Phase:
Study Start date:
August 08, 2024
Estimated Completion Date:
July 31, 2029

Connect with a study center

  • UZ Brussel

    Jette, 1090
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.